Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
16.25
-0.25 (-1.52%)
At close: Mar 9, 2026

Meribank Biotech Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
1,4302,4632,392---
Upgrade
Market Cap Growth
-28.10%2.99%----
Upgrade
Enterprise Value
2,4412,5422,260---
Upgrade
Last Close Price
16.2527.9938.09---
Upgrade
PS Ratio
2.946.7210.21---
Upgrade
PB Ratio
1.182.023.56---
Upgrade
P/TBV Ratio
4.067.263.81---
Upgrade
EV/Sales Ratio
5.026.949.64---
Upgrade
Debt / Equity Ratio
0.940.770.050.100.090.18
Upgrade
Net Debt / Equity Ratio
0.830.64-0.54-0.34-0.40-0.07
Upgrade
Net Debt / EBITDA Ratio
143.54-15.323.301.652.710.47
Upgrade
Net Debt / FCF Ratio
28.32-2.7110.293.567.721.09
Upgrade
Asset Turnover
0.240.200.250.200.190.27
Upgrade
Inventory Turnover
26.1119.0112.4414.1722.3328.36
Upgrade
Quick Ratio
1.371.434.213.304.542.36
Upgrade
Current Ratio
1.581.694.493.604.792.58
Upgrade
Return on Equity (ROE)
-7.43%-10.27%-22.62%-19.46%-20.48%-13.33%
Upgrade
Return on Assets (ROA)
-1.65%-2.94%-8.01%-7.65%-7.25%-6.16%
Upgrade
Return on Capital Employed (ROCE)
-2.00%-3.60%-13.10%-14.90%-11.40%-11.10%
Upgrade
Earnings Yield
-4.68%-3.84%-5.24%---
Upgrade
FCF Yield
2.47%-11.64%-1.48%---
Upgrade
Buyback Yield / Dilution
-31.49%-26.54%-0.11%-4.07%-14.52%-0.16%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.